Durability of viral response after off-treatment in HBeAg positive chronic hepatitis B

Table 4 Multivariate analysis on predictive factors of virological recurrence after withdrawal of antiviral treatment

	Regression coefficent	Standard error	P value	RR (95% CI)
Age ( ≤ 40 yr vs > 40 yr)	-1.17	0.596	0.049	0.310 (0.096-0.998)
Sex (male vs female)	-0.938	0.527	0.075	0.391 (0.139-1.099)
Pretreatment ALT level (< 2 × ULN vs≥ 2 × ULN)	-2.11	1.135	0.063	0.121 (0.013-1.121)
Pretreatment HBV DNA level (< 108 vs≥ 108)	-0.27	0.533	0.612	0.763 (0.268-2.170)
Time to undetectable HBV (< 6 mo vs≥ 6 mo)	-0.237	0.635	0.709	0.789 (0.227-2.739)
Time to HBeAg seroconversion (< 12 mo vs≥ 12 mo)	1.417	0.846	0.094	4.126 (0.786-21.66)
Consolidation treatment (< 15 mo vs≥ 15 mo)	2.425	0.87	0.005	11.299 (2.054-65.12)
Total treatment duration (< 24 mo vs≥ 24 mo)	0.001	0.732	0.999	1.001 (0.238-4.207)
Antiviral agent (entecavir vs clevudine)	-1.529	0.861	0.076	0.217 (0.040-1.172)

HBV: Hepatitis B virus; HBeAg: Hepatitis B e antigen; ULN: Upper limit of normal; ALT: Alanine aminotransferase; RR: Relative risk.